What is the recommended antibiotic treatment for bursitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antibiotic Treatment for Bursitis

For septic bursitis, antibiotics effective against Staphylococcus aureus are the first-line treatment, with intravenous cloxacillin 2g every 4 hours until improvement, followed by oral cloxacillin 1g every 6 hours until resolution. 1

Diagnosis of Septic vs. Non-Septic Bursitis

Proper diagnosis is crucial before initiating antibiotic therapy:

  • Septic bursitis should be distinguished from non-infectious causes (traumatic, microtraumatic, inflammatory) 2
  • Key physical findings suggestive of septic bursitis include:
    • Tenderness (present in 88% of septic cases vs 36% of aseptic cases) 3
    • Erythema/cellulitis (83% septic vs 27% aseptic) 3
    • Warmth (84% septic vs 56% aseptic) 3
    • Evidence of trauma or skin lesion (50% septic vs 25% aseptic) 3
    • Fever (38% septic vs 0% aseptic) 3
  • Bursal aspiration with fluid analysis is essential when infection is suspected 2
    • Fluid should be examined with Gram stain, crystal analysis, glucose measurement, cell count, and culture 2

Antibiotic Treatment Algorithm for Septic Bursitis

First-Line Treatment:

  • Staphylococcus aureus is the most common pathogen (94.4% of culture-positive cases) 1
  • Cloxacillin/flucloxacillin is the recommended first-line treatment: 4, 1
    • Intravenous: 2g every 4 hours until clinical improvement
    • Then oral: 1g every 6 hours until resolution
    • Total duration: 2-3 weeks 4

For Severe Cases (extensive cellulitis or systemic symptoms):

  • Cloxacillin plus gentamicin (240mg/day IV for 5-7 days) 1
  • Alternative regimen: cloxacillin plus rifampicin (600mg/day orally) 1

For Penicillin-Allergic Patients:

  • Vancomycin (15mg/kg every 12 hours IV) 4
  • Clindamycin (600-900mg every 8 hours IV) 4

For MRSA Coverage:

  • Vancomycin (15mg/kg every 12 hours IV) 4
  • Linezolid, quinupristin/dalfopristin, or daptomycin for resistant strains 4

Management Principles

  • Outpatient oral antibiotics may be considered for patients who are not acutely ill 2
  • Hospitalization with IV antibiotics is indicated for patients who are acutely ill 2
  • Antibiotics should be administered intravenously initially, then switched to oral once clinical improvement occurs 4
  • Repeat imaging (MRI preferred) should be performed in patients with persistent bacteremia to identify undrained foci of infection 4

Surgical Considerations

  • Early drainage of purulent material should be performed 4
  • Surgical intervention is typically reserved for cases not responsive to antibiotics or for recurrent cases 2
  • Endoscopic bursectomy may be considered for patients requiring surgical debridement to decrease morbidity 5

Special Considerations

  • For immunocompromised patients or those with open trauma to the area, add an agent active against enteric gram-negative bacilli 4
  • For polymicrobial infections (less common), broader coverage may be needed:
    • Ampicillin-sulbactam, piperacillin-tazobactam, or a carbapenem 4
    • Ceftriaxone plus metronidazole 4
    • Ciprofloxacin plus metronidazole 4

Non-Infectious Bursitis

  • Acute traumatic/hemorrhagic bursitis: conservative treatment with ice, elevation, rest, and analgesics 2
  • Chronic microtraumatic bursitis: address underlying cause; bursal aspiration generally not recommended due to risk of iatrogenic infection 2
  • Inflammatory bursitis (e.g., gout, rheumatoid arthritis): treat underlying condition 2

References

Research

Common Superficial Bursitis.

American family physician, 2017

Research

Olecranon bursitis.

Journal of shoulder and elbow surgery, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Recent developments in septic bursitis.

Current infectious disease reports, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.